Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

isone and in 10% of patients treated with irofulven + prednisone. No PSA responses were observed following treatment with mitoxantrone + prednisone. Treatment related toxicity including Grade 3-4 myelosuppression was manageable in all 3 arms. These results support further study of irofulven in this setting.

Additional Abstracts Presented at the 2007 ASCO Annual Meeting

Abstract # 7080

"Changing the treatment paradigm for patients with MDS: how the development of therapeutics influences population-based care in community oncology - the Georgia Cancer Specialists Outcomes Database experience"

Abstract # 7088

"Phase II trial of decitabine in myelofibrosis with myeloid metaplasia"

Abstract # 9565

"Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): A Children's Oncology Group Study"

Abstract # 2036

"Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme"

Abstract #34157

"A retrospective safety and efficacy analysis of combination therapy for GBM using temozolomide, external beam radiation (EBRT), and Gliadel Wafers"

About Aloxi(R) Injection

Aloxi is approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Aloxi is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderately emetogenic cancer chemotherapy. In clinical trials, the most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Please see t
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/19/2014)... using intact cells to treat and cure disease ... it is hindered by the inability of doctors and ... of these cells in patients without resorting to invasive ... September 17 in the online journal Magnetic Resonance ... San Diego School of Medicine, University of Pittsburgh and ...
(Date:9/19/2014)... published today in the online journal PLoS Outbreaks ... West Africa by the end of the month if ... State University and Harvard University researchers also discovered through ... significantly increased in August in Liberia and Guinea, around ... place, indicating that the mass quarantine efforts may have ...
(Date:9/19/2014)... Fla. Researchers at Jacksonville,s campus of Mayo Clinic ... they say contributes to both overproduction of toxic protein ... as well as loss of communication between neurons ... Their study, in the online issue of ... specific defect with drugs "may rejuvenate or rescue this ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
(Date:9/19/2014)... (Sept. 19, 2014) Shahram Majidi, M.D., a ... the George Washington University School of Medicine and ... American Heart Association to study the presence of ... intracerebral hemorrhage (ICH). , "According to epidemiological studies, ... of all strokes, but is the least treatable ...
Breaking Medicine News(10 mins):Health News:A better way to track emerging cell therapies using MRIs 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2
... Stem cell research holds promise for improving the quality of ... develop into any tissue in the human body. However, basic ... researchers are leading the way to inventive solutions. ... and safe therapeutic tool, we have to find strategies to ...
... cafeterias and other food-service providers? A new study from North ... cameras in commercial kitchens to see how precisely food handlers ... more often than previously thought. "Meals prepared outside the ... food poisoning outbreaks, making them a vital focus area for ...
... U.S. Food and Drug Administration,s abilities to discover potential ... illness are hampered by impediments to efficient use of ... and using information on risks, says a new report ... To more proactively tackle food safety problems, ...
... is influenced by our personality traits, according to new research ... published yesterday (7 June 2010) in the Proceedings of ... higher levels of neuroticism and more extravert men, are likely ... societies with traditionally high birth rates. The study ...
... extra sleep over an extended period of time improves ... abstract that will be presented Tuesday, June 8, 2010, ... annual meeting of the Associated Professional Sleep Societies LLC. ... significantly after seven to eight weeks of sleep extension. ...
... for patients in just the first six months after they ... in Canada, according to a study presented today at the ... Ischemic Stroke (BURST) study found that the direct and indirect ... in the six-month period following a new stroke. There are ...
Cached Medicine News:Health News:A launchpad for stem cell research 2Health News:Video study finds risky food-safety behavior more common than thought 2Health News:Video study finds risky food-safety behavior more common than thought 3Health News:FDA should adopt risk-based approach to food safety 2Health News:FDA should adopt risk-based approach to food safety 3Health News:Research shows personality can predict fertility 2Health News:Getting extra sleep improves the athletic performance of collegiate football players 2Health News:Cost of caring for stroke patients double that of earlier estimates 2Health News:Cost of caring for stroke patients double that of earlier estimates 3
... These objectives provide incredible image flatness over ... correction of chromatic aberration throughout the entire,visible ... for routine laboratory work but for photomicrography. ... series have more contrast than the DLL ...
... for this class of objectives. Correction ... with performance similar to the CFI Plan ... for spherical aberration and provide image flatness ... The DL phase contrast objectives in this ...
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark...
... scientist who wants a fully automated, computer-controlled ... high precision Z-focus automated microscope featuring a ... possible to expand the infinity space to ... A five-way automated light path with ...
Medicine Products: